Inovio announces the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share. The company will also offer pre-funded warrants to purchase 2 ...

Inovio Pharmaceuticals (NASDAQ: INO) is definitely not a company to bet the farm on, even if youre an audacious investor. However, the companys determination to address communicable diseases with ...

Shares of Inovio Pharmaceuticals Inc. INO slipped 1.84% to $2.13 Thursday, on what proved to be an all-around mixed trading ...

Inovio stock reached a COVID-19 pandemic bottom of $3.14 in February 2020. In June 2020, Inovio's stock reached its highest post-pandemic level of $33.79. See what Wall Street is buying with instant ...

Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering ...

Inovio Pharmaceuticals (INO) shares soared 6.8% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Inovio is on track for filing its BLA for INO-3107 in the latter half of 2024. INO-3107 has little in the way of pipeline support. Expect significant dilution as Inovio proceeds with its BLA and ...

Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...